Q&A: What the TECOS cardiac safety trial means for your type 2 diabetes patients

Sitagliptin Q&A

ORAL diabetes agent sitagliptin (Januvia) demonstrated cardiovascular safety in patients with pre-existing cardiovascular disease including heart failure, according to results from a large multinational cardiac safety trial.1